Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01558492 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01558492 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 3 participants.
The verdict
NCT01558492, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of prostate tumor progression and perhaps predict which patients may benefit from this chemotherapy regimen.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01558492
The ClinicalTrials.gov registry entry for NCT01558492 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01558492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01558492 about?
NCT01558492 is a clinical study titled "Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer". The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of pro...
What is the current status of trial NCT01558492?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01558492?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01558492?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.